NCT03826693 Efficacy of Nitrous Oxide in OCD: Pilot Study
| NCT ID | NCT03826693 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Stanford University |
| Condition | Obsessive-Compulsive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2021-04-17 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 45 participants in total. It began in 2021-04-17 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates whether the commonly used and well-tolerated inhaled anesthetic nitrous oxide can rapidly improve symptoms of OCD.
Eligibility Criteria
Inclusion Criteria: * Age 18-65 * Primary diagnosis of OCD * Sufficient severity of OCD symptoms * Ability to tolerate a treatment-free period * Capacity to provide informed consent Exclusion Criteria: * Psychiatric or medical conditions that make participation unsafe * Pregnant or nursing females * Concurrent use of any medications that might increase the risk of participation (e.g. drug interactions)
Contact & Investigator
Peter J van Roessel, MD, PhD
PRINCIPAL INVESTIGATOR
Stanford Univeristy
Frequently Asked Questions
Who can join the NCT03826693 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Obsessive-Compulsive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03826693 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT03826693 currently recruiting?
Yes, NCT03826693 is actively recruiting participants. Contact the research team at ocdresearch@stanford.edu for enrollment information.
Where is the NCT03826693 trial being conducted?
This trial is being conducted at Stanford, United States.
Who is sponsoring the NCT03826693 clinical trial?
NCT03826693 is sponsored by Stanford University. The principal investigator is Peter J van Roessel, MD, PhD at Stanford Univeristy. The trial plans to enroll 45 participants.